Views & Analysis The Simulated Cell: can a digital model aid cancer drug disc... Can a simulated cell hold the key to sky-high attrition rates between cancer drug discovery and approval?
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News Pfizer chief suggests no BMS bid - for now Ian Read won't quash rumours that his company Pfizer could swoop for vulnerable Bristol-Myers Squibb - but says it won't make any major acquisitions
News Sales of Keytruda double ahead of key lung cancer decision FDA to make decision on wider lung cancer use within a week.
News Takeda gets return on Ariad buy with approval of brigatinib But Japanese pharma bracing for US patent expiry on blockbuster Velcade
News Chinese trial backs base-editing drug for thalassaemia A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
